72
Participants
Start Date
February 28, 2025
Primary Completion Date
December 31, 2027
Study Completion Date
December 31, 2028
LM-108 injection
LM-108 injection is a monoclonal antibody that selectively clears regulatory T cells that infiltrate tumor sites.
Penpulimab injection
Penpulimab injection is a Programmed Cell Death Protein 1 (PD-1) immune checkpoint inhibitor.
Paclitaxel for injection (albumin bound)
Paclitaxel for injection (albumin bound) is a cytotoxic anticancer drug
Gemcitabine hydrochloride for injection
Gemcitabine hydrochloride for injection is a cell cycle specific anti-tumor drug that can inhibit the growth of tumor cells and belongs to a type of chemotherapy drug.
Peking Union Medical College Hospital, Beijing
Cancer Hospital Chinese Academy of Medical Science, Beijing
Beijing Cancer Hospital, Beijing
The First Affiliated Hospital of China Medical University, Shenyang
The Sixth People's Hospital of Shenyang, Shenyang
Harbin Medical University Cancer Hospital, Harbin
The First Affiliated Hospital of Naval Medical University, Shanghai
Jiangsu Cancer Hospital, Nanjing
Jiangsu Provincial People's Hospital, Nanjing
Tianjin Cancer Hospital Airport Hospital, Tianjin
Tianjin Medical University Cancer Institute & Hospital, Tianjin
The First Affiliated Hospital of Nanchang University, Nanchang
Chongqing Qeneral Hospital, Chongqing
Huazhong University of Science and Technology Tongji Medical College of Huazhong University of Science and Technology, Wuhan
The First Affiliated Hospital of Zhengzhou University, Zhengzhou
The First Affiliated Hospital of Xi'an Jiaotong University Medical College, Xi'an
Lead Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
INDUSTRY